Poster Session 09 Program Schedule
02/16/2024
03:30 pm - 04:45 pm
Room: Shubert Complex (Posters 1-60)
Poster Session 09: Epilepsy | Oncology | MS | Infectious Disease
Final Abstract #5
Poster Symposium: Neuropsychology in the Era of SARS-CoV-2 — Abstract 4
The Cognitive Effects of SARS-CoV-2
Jacqueline Becker, Icahn School of Medicine at Mount Sinai, New York, United States
Category: Other
Keyword 1: neuropsychological assessment
Keyword 2: cognitive functioning
Keyword 3: executive functions
Objective:
A number of patients with post-acute sequelae of SARS-CoV-2 (PASC) report new onset cognitive impairment, even months after acute infection. The objective of this presentation is to provide a detailed characterization of the cognitive deficits associated with PASC, including terminology, cognitive profile, severity, and trajectory, and to discuss research methodology in relation to other existing data on this topic.
Participants and Methods:
There will be a review of the data analyzed from the Mount Sinai Health System Post-COVID-19 Registry in New York City, a prospective cohort of patients post-COVID-19 ≥18 years of age (N= 1,562) and non-infected controls (N= 151) who speak English or Spanish. Cognitive functioning was assessed utilizing validated neuropsychological measures an average of 11 months after acute COVID-19, across the spectrum of disease severity.
Results:
Patients with PASC-related cognitive deficits are significantly more likely than controls to have impairment in executive functioning; however, there are no differences across other cognitive domains. Other studies have inherent selection biases, have failed to utilize objective, well-validated neuropsychological measures, and often lacked inclusion of racially and ethnically diverse populations.
Conclusions:
This presentation will provide an overview of the current research on the cognitive effects of PASC, with an emphasis on research methodology, psychosocial effects of the pandemic, and the impact on healthcare systems and underserved populations. Stigma, barriers to care, and common misconceptions will also be discussed, as will implications for clinicians (e.g., disability applications, performance validity) and researchers (e.g., psychometrics and measurement).
|